# Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)

> **NCT03833362** · PHASE3 · COMPLETED · sponsor: **R-Pharm** · enrollment: 420 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Narlaprevir
- **DRUG:** Ritonavir
- **DRUG:** Placebo Narlaprevir
- **DRUG:** Placebo Ritonavir
- **DRUG:** Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT03833362
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-07
- **Primary completion:** 2016-03-23
- **Final completion:** 2017-02-21
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2019-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833362, "Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03833362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*